Immunotherapy Could Stop Resistance to Radiotherapy
Results of the study—funded by MedImmune, the global biologics research and development arm of AstraZeneca, and Cancer Research UK—have been published in Cancer Research, a peer-reviewed journal published by the American Association for Cancer Research.
Around Half of All Cancer Patients Receive Radiotherapy
Radiotherapy is a very successful treatment for many forms of cancer, and data indicate that radiotheraphy is given to nearly half of all cancer patients. "(It) has been at the heart of helping improve survival rates so that today one in two cancer patients will survive for at least 10 years," said Professor Nic Jones, chief clinician at Cancer Research UK.
However, in cancer cells that radiotherapy does not kill it can switch on a "flag" on their surface, called PD-L1, that tricks the body's defences into thinking that cancerous cells pose no threat, the research team explained. Immunotherapy is able to block these "flags" to reveal the true identity of cancer cells, allowing the immune system to see them for what they are and destroy them. The approach improved survival and protected the mice against the disease from returning.
"Doctors and researchers are constantly looking for ways to improve treatments and this approach could open the door to a whole new way of giving radiotherapy," Prof. Jones noted.
Immunotherapies Have Huge Potential
Using the body's own defences to treat cancers has huge potential, with early phase clinical trials showing exciting patient benefit, said Dr. Simon Dovedi, the lead author based at The University of Manchester and member of the Manchester Cancer Research Centre. "(We) are still at the early stages of understanding how best to use these types of treatments. Combining certain immunotherapies with radiotherapy could make them even more effective and we're now looking to test this in clinical trial to see just how much of a difference it could make," Dr. Dovedi pointed out.
Results of the recent study with Cancer Research UK are very encouraging, according to Dr. Robert Wilkinson, Director of Oncology Research, MedImmune. He said that MedImmune "is committed to developing strong science led collaborations, and supporting research that helps further advance our scientific understanding in the important area of immunotherapy."
Cancer Research UK joined forces with The Christie NHS Foundation Trust and The University of Manchester to form the Manchester Cancer Research Centre, allowing scientists and doctors to work closely together to turn scientific advances into patient benefits sooner.
Image Credit: Wikimedia Commons
Published on : Mon, 6 Oct 2014
The next level in usability ARIETTA 50LE is the compact entry model of the ARIETTA series, inviting easy operation from beginners through experts, taking you to the ‘next level’. This ultrasound platform combines Carefree Workflow, Clear...
Remarkable image quality, right at the point of care. The Trident system revolutionizes breast tissue imaging by incorporating a micro-focused tube, unique specimen image processing algorithms and amorphous selenium direct digital detector. The...
BioZorb® 3D Bioabsorbable Marker The BioZorb® is a 3D implantable marker that consists of a spiral, bioabsorbable framework embedded with 6 permanent, titanium clips designed to precisely mark your surgical excision site. Designed to improve outcomes...
A breakthrough in biopsy efficiency The Brevera system streamlines the entire breast biopsy process from start to finish – with real-time imaging for instant verification and automated post-biopsy specimen handling. This has the potential to...
Better detection. Clinically superior. Low dose.** What if we could find breast cancers earlier? See lesions more clearly? Reduce the number of unnecessary biopsies? Questions like these inspired Hologic researchers and scientists to develop Hologic...